Less Invasive More Reassuring
Less Invasive More Reassuring
| Comparison |
The Wei Procedure (TA-BSM) |
Standard Septal Myectomy |
| Incision | Minimally invasive apical access | Large open-chest incision |
| Cardiopulmonary bypass | Not required | Required |
| Procedure Time | Avg. 1.28 hours | 3 - 6 hours |
| Recovery | Faster recovery, less trauma | Slow recovery, longer hospital stay |
| Patient Eligibility | Suitable for pediatric/geriatric/ non-obstructive patients | Limited by age or comorbidities |
The Vass M1 is a minimally invasive surgical device specifically developed for The Wei Procedure, also known as the Transapical Beating-Heart Septal Myectomy. This innovative technique performs septal resection through a small apical incision while the heart continues to beat, eliminating the need for cardiopulmonary bypass.
Vass M1 integrates precision, safety, and ease of use to support the standardized implementation of this procedure across a broader range of medical centers.
The Vass M1 is indicated for patients with both obstructive and non-obstructive hypertrophic cardiomyopathy who remain symptomatic despite optimal medical therapy.
It addresses conditions such as:
Reduced Learning Curve
Lowers learning and resource requirement, easier adoption
Better Operability
Intuitive design and operability, real-time guidance under TEE
Easier to Learn
Immediate feedback upon resection, no more guessing
Standardized Workflow
Reduces reliance on surgeon experience, facilitates replication and training
Broad Center Compatibility
No need for specialized equipment, adaptable to diverse hospitals
Reduced Learning Curve
Lowers learning and resource requirement, easier adoption
Better Operability
Intuitive design and operability, real-time guidance under TEE
Easier to Learn
Immediate feedback upon resection, no more guessing
Standardized Workflow
Reduces reliance on surgeon experience, facilitates replication and training
Broad Center Compatibility
No need for specialized equipment, adaptable to diverse hospitals
Patented technology across the globe
Featured in the National Key R&D Program of China
Recipient of first prize in technological invention (Hubei Province, 2023), along with multiple provincial and municipal awards for clinical innovation and research excellence
First prize winner at the 6th China medical device innovation and entrepreneurship competition
Featured at major international cardiothoracic surgery conferences, including AATS, EACTS, and STS
Appeared in many international cardiac surgery conferences (AATS, EACTS, STS, etc.)
Won the first prize of the 6th China Medical Device Innovation and Entrepreneurship Competition
Obtained invention patents from both China and the United States
Incorporate into the national key research and development plan for support
National and Provincial Awards
The novel device and surgical approach for transapical myectomy developed by Dr Wei and his team may be an important step in expanding surgery for Septal Reduction Therapy.
Dr. Hartzell Schaff
